In the most common type of non-Hodgkin lymphoma (NHL) —– diffuse large B-cell lymphoma (DLBCL), four circulating miRNAs (miR-21, miR-130b, miR-155, and miR-28) are considered to be novel prognosis biomarkers of DLBCL and modulate RAS protein signaling transduction via Insuline-like growth factor I(IGF1) and Jun. This evidence concerns the gene IGF1 and diffuse large B-cell lymphoma.